Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7295324 | 0.89 | DAO (0.47) | DAOMCL1POLBKMT2ANPC1 | |
| SCHEMBL4672103 | 0.84 | OXER1 (0.52) | KMT2A | |
| SCHEMBL28223276 | 0.83 | OXER1 (0.53) | — | |
| SCHEMBL1744581 | 0.82 | KMT2A (0.53) | DAOMCL1POLBKMT2ANPC1 | |
| SCHEMBL30005781 | 0.81 | KMT2A (0.46) | MCL1KMT2AKDM1A | |
| SCHEMBL3696937 | 0.81 | OXER1 (0.54) | — | |
| SCHEMBL7072559 | 0.80 | KMT2A (0.47) | DAOMCL1POLBKMT2AKDM1A | |
| SCHEMBL28614887 | 0.80 | KMT2A (0.45) | POLBKMT2AKDM1A | |
| SCHEMBL663 | 0.79 | POLB (0.47) | DAOPOLBKMT2AKDM1A | |
| SCHEMBL1122203 | 0.79 | OXER1 (0.62) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110536884-A | synthesis of MCL-1 inhibitors | ASTRAZENECA AB | 2019-12-03 | — | — | CN | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2015-10-08 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| WO-2014068341-A2 | CHIRAL FLUORINATING REAGENTS | ISIS INNOVATION LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| US-8697739-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-6596738-B1 | Inhibiting activity to adenosine deaminase (hereinafter described as ADA) An adenosine deaminase inhibiting agent comprising a compound of the formula (I): | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | DAO 1171/4885MCL1 3455/4885POLB 1792/4885 |
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | TIAM1, AFF2, AFF1 | DAO 10/4885MCL1 829/4885POLB 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.